Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

The adoptive transfer of antigen-specific T cells that have been expanded ex vivo is being actively pursued to treat infections and malignancy in humans. The T cell populations that are available for adoptive immunotherapy include both effector memory and central memory cells, and these differ in phenotype, function, and homing. The efficacy of adoptive immunotherapy requires that transferred T cells persist in vivo, but identifying T cells that can reproducibly survive in vivo after they have been numerically expanded by in vitro culture has proven difficult. Here we show that in macaques, antigen-specific CD8(+) T cell clones derived from central memory T cells, but not effector memory T cells, persisted long-term in vivo, reacquired phenotypic and functional properties of memory T cells, and occupied memory T cell niches. These results demonstrate that clonally derived CD8+ T cells isolated from central memory T cells are distinct from those derived from effector memory T cells and retain an intrinsic capacity that enables them to survive after adoptive transfer and revert to the memory cell pool. These results could have significant implications for the selection of T cells to expand or to engineer for adoptive immunotherapy of human infections or malignancy.

[1]  M. Merkenschlager,et al.  Chromatin structure and gene regulation in T cell development and function. , 2006, Current opinion in immunology.

[2]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[3]  Leo Lefrançois,et al.  Initial T cell frequency dictates memory CD8+ T cell lineage commitment , 2005, Nature Immunology.

[4]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[5]  T. Wyss-Coray,et al.  Antigen‐presenting human T cells and antigen‐presenting B cells induce a similar cytokine profile in specific T cell clones , 1993, European journal of immunology.

[6]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[7]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[8]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[9]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[10]  P. Lansdorp,et al.  Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry , 1998, Nature Biotechnology.

[11]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[12]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[13]  P. Greenberg,et al.  Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. , 1980, Journal of immunology.

[14]  V. ter meulen,et al.  Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys. , 2003, Blood.

[15]  P. Lansdorp,et al.  Telomere length measurements in leukocyte subsets by automated multicolor flow‐FISH , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[16]  E. Wherry,et al.  Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells , 2002, The Journal of experimental medicine.

[17]  Andrew J. McMichael,et al.  Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets1 , 2005, The Journal of Immunology.

[18]  D. Fearon,et al.  Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.

[19]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[20]  D. Srivastava,et al.  Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .

[21]  C. Pitcher,et al.  Development and Homeostasis of T Cell Memory in Rhesus Macaque1 , 2002, The Journal of Immunology.

[22]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Deegen,et al.  Highly Protective In Vivo Function of Cytomegalovirus IE1 Epitope-Specific Memory CD8 T Cells Purified by T-Cell Receptor-Based Cell Sorting , 2005, Journal of Virology.

[24]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[25]  T. Waldmann,et al.  The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.

[26]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[27]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[28]  T. Waldmann,et al.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[31]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[32]  E. Mocarski,et al.  Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[34]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[35]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[36]  E. Warren,et al.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.

[37]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[38]  L. Lefrançois,et al.  The descent of memory T-cell subsets , 2006, Nature Reviews Immunology.

[39]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[40]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[41]  S. Riddell,et al.  Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.

[42]  T. Blankenstein,et al.  Retroviral vectors for high-level transgene expression in T lymphocytes. , 2003, Human gene therapy.

[43]  E John Wherry,et al.  The role of programming in memory T-cell development. , 2004, Current opinion in immunology.

[44]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[45]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Heimfeld,et al.  Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. , 2004, Blood.

[47]  S. Riddell,et al.  Nonmyeloablative Immunosuppressive Regimen Prolongs In Vivo Persistence of Gene-Modified Autologous T Cells in a Nonhuman Primate Model , 2001, Journal of Virology.

[48]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[49]  L. Lefrançois,et al.  Cutting Edge: Requirement for IL-15 in the Generation of Primary and Memory Antigen-Specific CD8 T Cells1 , 2002, The Journal of Immunology.

[50]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[51]  H. Broxmeyer,et al.  Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26 , 2004, Science.

[52]  H. Heslop,et al.  Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.